Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
For dental patients undergoing deep sedation or general anaesthesia, best practices include holding daily GLP-1 agonists on the day of procedure and weekly GLP-1 agonists a week prior to procedure, and adhering to or extending the current ASA fasting guidelines, with the possibility of an addition period of a clear fluid diet ahead of the recommended fasting period
Proper administration technique, dosage timing, and storage are crucial to maximising therapeutic benefits and minimising side effects
Reconstitution Add 1mL of bacteriostatic water to get a solution that is 10mg/mL, such that every 0.1mL (10 units on an insulin syringe) is equal to 1mg of Retatrutide
Oral semaglutide and cardio-vascular outcomes in patients with type 2 diabetes
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
US$ 26.07
US$ 25.50
US$ 29.06
US$ 29.65
US$ 26.93
